Table 3.

Results of multivariate analysis of transplant-outcomes after unrelated donor peripheral blood stem cell and bone marrow transplantations by leukemia type and disease status at transplantation

Outcome	N1/N2	Relative Risk* (95% confidence interval)	P-value
Transplant-related mortality
AL/MDS, CR1, RA	95/119	0.78 (0.52 – 1.19)	0.256
AL/MDS, CR2, Relapse, RAEB, RAEBT	170/296	0.86 (0.65 – 1.16)	0.328
CL, CP1	28/103	1.71 (0.97 – 3.01)	0.062
CL, CP2, AP, BP	38/67	0.97 (0.49 – 1.90)	0.928
Relapse
AL/MDS, CR1, RA	95/119	0.83 (0.44 – 1.55)	0.554
AL/MDS, CR2, Relapse, RAEB, RAEBT	170/296	0.85 (0.60 – 1.19)	0.345
CL, CP1	28/103	0.76 (0.09 – 6.31)	0.800
CL, CP2, AP, BP	38/67	1.30 (0.64 – 2.64)	0.462
Treatment failure
AL/MDS, CR1, RA	95/119	0.78 (0.55 – 1.11)	0.172
AL/MDS, CR2, Relapse, RAEB, RAEBT	170/296	0.85 (0.68 – 1.06)	0.151
CL, CP1	28/103	1.64 (0.95 – 2.82)	0.074
CL, CP2, AP, BP	38/67	1.12 (0.69 – 1.82)	0.650
Overall mortality
AL/MDS, CR1, RA	95/119	0.78 (0.55 – 1.11)	0.174
AL/MDS, CR2, Relapse, RAEB, RAEBT	170/296	0.86 (0.68 – 1.07)	0.174
CL, CP1	28/103	1.89 (1.09 – 3.27)	0.023
CL, CP2, AP, BP	38/67	0.96 (0.58 – 1.59)	0.889

N1=number of evaluable PBSC recipients; N2=number of evaluable BM recipients

^*Baseline: bone marrow; relative risk of less than 1.00 and p≤0.05 indicate an advantage for peripheral blood stem cell.

Abbreviations: AL=acute leukemia; MDS=myelodysplastic syndrome; CL=chronic myeloid leukemia; CR= clinical remission; RA=refractory anemia; RAEB/RAEBT=refractory anemia with blasts or in transformation; CP=chronic phase; AP=accelerated phase; BP=blast phase